As FGF21 has been shown to reduce glucose and lipid levels, it has been suggested as a potential therapeutic agent for the treatment of diabetes, obesity, and dyslipidemia [3]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.